SMC
ALT icon

Smith, Moore & Co’s Altimmune ALT Stock Holding History

Smith, Moore & Co’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.1K Hold
13,205
– – ﹤0.01% 586
2026
Q1 		$40.7K Buy
+13,205
New +$56.1K ﹤0.01% 557

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smith, Moore & Co's ALT Position: Q2 2026 in Review

Smith, Moore & Co held its Altimmune (ALT) position steady in Q2 2026 at 13,205 shares worth $40.1K. The position accounts for ﹤0.01% of the portfolio, ranked #586.

Smith, Moore & Co first reported a position in ALT in Q1 2026 and has held it in 2 quarters since. The position peaked at $40.7K in Q1 2026. 211 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Smith, Moore & Co held 13,205 shares of Altimmune worth $40.1K as of Q2 2026.
  • Smith, Moore & Co left its Altimmune share count unchanged in Q2 2026.
  • Altimmune made up ﹤0.01% of Smith, Moore & Co's portfolio in Q2 2026, its #586 holding.
  • Smith, Moore & Co first reported a position in Altimmune in Q1 2026 and has held it in 2 quarters since.
  • Smith, Moore & Co's Altimmune position peaked at $40.7K in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Smith, Moore & Co's 13F filing for Q2 2026, filed 12 Aug 2026.